Drug Trial Radar · NCT04866134
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
May 7, 2021
Primary completion
Jul 1, 2026
Study completion Jul 1, 2026
Sponsor
- Lead sponsor
- Erasca, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. * To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors
Conditions
- Advanced or Metastatic Solid Tumors
Interventions
ERAS-007Drug
ERAS-007 will be administered orally as specified in Arm description.
ERAS-601Drug
ERAS-601 will be administered orally as specified in Arm description.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate safety and tolerability of escalating doses of ERAS-007 BID-QWTime frame: Assessed up to 24 months from time of first dose
- Dose Limiting Toxicities (DLT)Time frame: Study Day 1 up to Day 29
- Maximum tolerated dose (MTD)Time frame: Study Day 1 up to Day 29
- Recommended dose (RD)Time frame: Study Day 1 up to Day 29
- Adverse EventsTime frame: Assessed up to 24 months from time of first dose
- Plasma concentration (Cmax)Time frame: Study Day 1 up to Day 29
- Time to achieve Cmax (Tmax)Time frame: Study Day 1 up to Day 29
- Area under the curveTime frame: Study Day 1 up to Day 29
- Half-lifeTime frame: Study Day 1 up to Day 29
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Sarah Cannon Research Institute (HealthONE)
Denver, Colorado
Sarah Cannon Research Institute (Florida Cancer Specialists)
Sarasota, Florida
Sarah Cannon Research Institute (Tennessee Oncology)
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
NEXT Oncology
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.